In this context, CXCR4 has been reported to be a therapeutic target because TGF-β signaling induces acetylation of the transcription factor KLF5 in PCa with BM, which activates CXCR4, leading to osteoclastogenesis and BM [47, 48]. This evidence concerns the gene CXCR4 and posterior cortical atrophy.